337 related articles for article (PubMed ID: 29950117)
21. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide as palliative treatment in patients with advanced secondary glioblastoma.
Hassler MR; Sax C; Flechl B; Ackerl M; Preusser M; Hainfellner JA; Woehrer A; Dieckmann KU; Rössler K; Prayer D; Marosi C
Oncology; 2015; 88(3):173-9. PubMed ID: 25427949
[TBL] [Abstract][Full Text] [Related]
24. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological strategies for improving the prognosis of glioblastoma.
Raj D; Agrawal P; Gaitsch H; Wicks E; Tyler B
Expert Opin Pharmacother; 2021 Oct; 22(15):2019-2031. PubMed ID: 34605345
[No Abstract] [Full Text] [Related]
26. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
27. Advanced magnetic resonance imaging to support clinical drug development for malignant glioma.
Kassubek R; Müller HP; Thiele A; Kassubek J; Niessen HG
Drug Discov Today; 2021 Feb; 26(2):429-441. PubMed ID: 33249294
[TBL] [Abstract][Full Text] [Related]
28. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
29. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy.
Nikaki A; Piperi C; Papavassiliou AG
Expert Opin Investig Drugs; 2012 Oct; 21(10):1475-88. PubMed ID: 22809292
[TBL] [Abstract][Full Text] [Related]
30. Advanced interstitial chemotherapy for treating malignant glioma.
Tseng YY; Kau YC; Liu SJ
Expert Opin Drug Deliv; 2016 Nov; 13(11):1533-1544. PubMed ID: 27248137
[TBL] [Abstract][Full Text] [Related]
31. Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Bartolini S; Brandes AA
Expert Opin Drug Discov; 2023 Mar; 18(3):269-286. PubMed ID: 36718723
[TBL] [Abstract][Full Text] [Related]
32. OX40 agonists for cancer treatment: a patent review.
Cebada J; Perez-Santos M; Bandala C; Lara-Padilla E; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L; Monjaraz E; Flores A; Anaya-Ruiz M
Expert Opin Ther Pat; 2021 Jan; 31(1):81-90. PubMed ID: 32945223
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
34. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
36. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
37. Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme.
Arévalo ÁST; Erices JI; Uribe DA; Howden J; Niechi I; Muñoz S; Martín RS; Monrás CAQ
Curr Med Chem; 2017; 24(25):2781-2795. PubMed ID: 28260500
[TBL] [Abstract][Full Text] [Related]
38. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
39. Frontiers in the treatment of glioblastoma: Past, present and emerging.
Janjua TI; Rewatkar P; Ahmed-Cox A; Saeed I; Mansfeld FM; Kulshreshtha R; Kumeria T; Ziegler DS; Kavallaris M; Mazzieri R; Popat A
Adv Drug Deliv Rev; 2021 Apr; 171():108-138. PubMed ID: 33486006
[TBL] [Abstract][Full Text] [Related]
40. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
